The government said it has signed an additional purchase contract for oral treatments (Paxlovid) with Pfizer Korea. According to the KDCA, a total of 1,004,000 oral treatments were pre-purchased through the contract, including 762,000 with Pfizer and 242,000 with MSD Korea.

Pfizer's oral treatment (Paxlovid) will be introduced in Korea in mid-January as scheduled. It is in the final stage of finalizing details with pharmaceutical companies, and plans to guide the public on how to introduce and utilize oral treatments next week.

With the introduction of oral treatments, the government expects that they will greatly help treat home patients, while also contributing to quarantine and medical